REC Ref.	IRAS No.	Name of Trial	Target Number	Minimum	Maximum	Target Date	Date	Total	Date That	Total	Reason For Closure Of
nee nen			Of Patients Agreed?		Number Of	f To Recruit	Agreed to	Number Of		Number Of	
							recruit	Patients	Closed To		
				Agreed		Agreed?	target			Participants	
				(Enter	(Enter		number of	At The	t	Recruited	
				Same In	Same In		patients	Agreed			
				Both If Only		,		Target Date			
				One	One						
				Number)	Number)						
17/LO/0380	218003	PET-LONGITUDINAL SUBSTUDY ASSOCIATED WITH: A PHASE III, MULTICENTER,	No			No a date is			19/06/2018	1	Recruitment finished
		RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP,				not					
		EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL				available /					
		TO MILD ALZHEIMER'S				was not					
		DISEASE				agreed					
17/NE/0151	223815	Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-	Yes, target	2		Yes a date	31/12/2018	0	14/09/2018	0	Withdrawn by Sponsor
		110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid	number agreed			was agreed					
		Leukemia (SGI-110-06).	_								
17/EE/0177	220722	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib,	Yes, target	3		Yes a date	01/06/2020	7	26/09/2018	7	Recruitment finished
		and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in	number agreed			was agreed					
		Patients with Relapsed or Refractory Multiple Myeloma (RRMM).									
17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the	Yes, target	2		No a date is			05/12/2017	1	Recruitment finished
		Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to	number agreed			not					
		Nonalcoholic Steatohepatitis (NASH)-STELLAR 4				available /					
						was not					
						agreed					
17/SC/0122	224090	AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut	Yes, target	12	12	Yes a date	01/12/2018		01/12/2017	12	Recruitment finished
		Allergic Children	number agreed			was agreed					
16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of	Yes, target		1	Yes a date	31/10/2017		07/11/2017		Recruitment finished
		ribociclib (LEE011) in combination with letrozole for the treatment of men and	number agreed			was agreed					
		pre/postmenopausal women with hormone receptor-positive (HR+) HER2-									
		negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy									
		for advanced disease.									
16/LO/1625	173719	Assessment of real life care - describing European heart failure management	Yes, target	10	20	Yes a date	29/04/2018		29/04/2018	20	Recruitment finished
			number agreed			was agreed					
17/LO/0783	225826	A Multicenter, Parallel-Group, Randomized, Cross-Over Trial to Compare the	Yes, target	4	4	Yes a date	14/05/2018	0	21/03/2018	0	Withdrawn by Sponsor
			number agreed			was agreed					
		Endocardial Border Definition									
17/LO/0096	220205	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy	Yes, target		2	no			02/03/2018		Withdrawn by Sponsor
			number agreed								
		Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from									
47/000000000000000000000000000000000000	00000	Natalizumab (SUSTAIN)				<u> </u>	4 - 14 - 10		47/05/05-5		
17/NW/0175	222859	A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult patients	Yes, target	1		Yes a date	15/11/2017		17/05/2018	2	Recruitment finished
			number agreed			was agreed	0.110/00/0		00/05/00/0		
17/LO/0304	222475	A double-blind, randomised, placebo-controlled, parallel-group, phase 2, dose-	Yes, target	10	12	Yes a date	31/10/2018	0	30/05/2018	0	Withdrawn by Sponsor
			number agreed			was agreed					
		10mg, 20mg and 40mg twice daily (BID) versus placebo in women with mixed									
		urinary continence									

17/EE/0081	219405	An open label, single arm pilot study of OncoSilâ,,¢, administered to study	Yes, target		2	Yes a date	01/06/2020		26/06/2018		Recruitment finished
_,,,		participants with unresectable locally advanced pancreatic adenocarcinoma,	number agreed			was agreed					
		given in combination with FOLFIRINOX or gemcitabine+nab-paclitaxel	indiniser ugreed			was agreed					
		chemotherapies.									
16/LO/2148		A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability	Yes, target	4	4	Yes a date	01/01/2018	8	07/01/2018	8	Recruitment finished
, ,		and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men	number agreed			was agreed					
		with Histologically Proven, Clinically Significant, Localised, Low- to Intermediate-	-								
		Risk Prostate Cancer that is Associated with an MRI Lesion									
17/NW/0026	209929	An observational study of the epidemiology of fever due to infection in critically	Yes, target	198	198	Yes a date	31/08/2017		31/08/2018	121	Recruitment finished
		ill children following an unplanned admission to a Paediatric Intensive Care Unit				was agreed					
		Fever Observational Study									
16/NE/0067	199159	A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of	Yes, target	4	4	Yes a date	31/12/2017		31/12/2017	6	Recruitment finished
		Deferiprone Delayed Release Tablets in Patients with Parkinson's Disease.	number agreed			was agreed					
16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF	Yes, target	2	2	Yes a date	31/10/2017		21/12/2017	0	Withdrawn by Sponsor
		MONGERSEN (GED-0301) IN	number agreed			was agreed					
		SUBJECTS WITH CROHN'S DISEASE									
16/EE/0357	206501	Efficacy and safety of opicapone in clinical practice in Parkinson's Disease	Yes, target	4	4	Yes a date	30/11/2017		30/11/2017	8	
		patients with wearing-off motor fluctuations	number agreed			was agreed					
16/LO/1891	213918	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability,	Yes, target	1	1	Yes a date	15/12/2017		15/12/2017	2	
		and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone	number agreed			was agreed					
		Alone in Subjects with Severe Alcoholic Hepatitis (AH)	_			_					
17/LO/0082	217324	A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and	Yes, target	3	3	Yes a date	31/12/2017		31/12/2017	6	
		Performance of PuraStat Absorbable Haemostatic Material for the Management	number agreed			was agreed					
		of Bleeding in Vascular Surgery									
17/EM/0005	215706	A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess	Yes, target		15	Yes a date	05/01/2020		29/01/2018		Withdrawn by Sponsor
		the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in	number agreed			was agreed					
		Subjects with Chronic Heart Failure with Reduced Ejection Fraction									
15/NE/0389	194347	Phase 1 study to assess Single Doses of ABY-035 in Healthy Subjects and	Yes, target		3	No a date is			01/02/2018	1	Recruitment finished
		Psoriasis	number agreed			not					
		Patients				available /					
						was not					
						agreed					
16/LO/0542	201528	An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and	Yes, target	4	4	Yes a date	31/01/2017		01/05/2018	2	Recruitment finished
		Efficacy of APL-130277 in Levodopa Responsive Patients with Parkinson's	number agreed			was agreed					
		Disease Complicated by Motor Fluctuations ("OFF" Episodes)									
17/LO/0052	212454	Evaluation of Uterine Patency following Sonography-guided Transcervical	Yes, target	10/01/1900	10/01/1900	Yes a date	01/11/2018	0	9 28/09/2018	9	Recruitment finished
		Ablation of Fibroids	number agreed			was agreed					
16/WM/0250	194366	A prospective, multi-national, multicentre, non-interventional study to evaluate	Yes, target	10/01/1900	10/01/1900	Yes a date	31/03/2018	(31/03/2018	4	Withdrawn by Sponsor
		the long term safety of Esmya, in particular the endometrial safety, and the	number agreed			was agreed					
		current prescription and management patterns of Esmya in a long term									
		treatment setting.									
16/NW/0728	211957	Investigation of the impact of healthcare professionals advice on the	no			No a date is			31/12/2017		Recruitment finished
		development of good sleep habits in babies under 12 months of age				not					
						available /					
						was not					
						agreed					
16/WM/0271	200160	Prospective, Single-Arm, Multi-Centre Study to Evaluate the Contour	Yes, target	10/01/1900	10/01/1900		07/07/2021		27/10/2017	1	5 Withdrawn by Sponsor
		Neurovascular Systemâ,,¢	number agreed			was agreed					

16/EM/0376	211430 The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy		03/01/1900		No a date is not	15/02/2018	0 15/02/2018	0 Recruitment finished
	and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects	number agreed			available /			
	with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week				was not			
	Extension Periods				agreed			
14/LO/0344	140294 A Phase 3, Open-Label, Randomized, Parallel, 2-Arm, Multi-Center	Yes, target	01/01/1900		Yes a date		20/04/2018	1 Recruitment finished
1,10,0011	Study of Talazoparib (BMN 673) versus Physician's Choice in	number agreed			was agreed		20,01,2010	
	Germline BRCA Mutation Subjects with Locally Advanced and/or				1100 001000			
	Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens							
	for Metastatic Disease							
16/LO/0675	147355 A PHASE 2, INTERNATIONAL, MULTICENTER, RANDOMIZED, OPENLABEL,	Yes, target	03/01/1900		Yes a date	31/10/2019	03/07/2018	0 Withdrawn by Sponsor
		number agreed			was agreed			
	(ORAL AZACITIDINE) ALONE AND IN COM+H768BINATION WITH DURVALUMAB	0			0			
	(MEDI4736) IN SUBJECTS WITH MYELODYSPLASTIC SYNDROMES WHO FAIL TO							
	ACHIEVE AN OBJECTIVE RESPONSE TO TREATMENT WITH AZACITIDINE FOR							
	INJECTION OR DECITABINE							
16/SS/0134	199690 A PHASE 1B MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND	Yes, target	03/01/1900	03/01/1900	Yes a date	28/02/2019	02/03/2018	0 Withdrawn by Sponsor
	TOLERABILITY AND DETERMINE THE MAXIMUM TOLERATED DOSE OF PF-	number agreed			was agreed			
	05230907 IN SUBJECTS	-			-			
16/NE/0084	196157 A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (nal-IRI)-	no			No a date is		0 18/04/2018	Withdrawn by Sponsor
	containing Regimens versus Gemcitabine plus nab-Paclitaxel in Patients with				not			
	Previously Untreated, Metastatic Pancreatic Adenocarcinoma				available /			
					was not			
					agreed			
16/LO/0118	191634 Valiant Evo International Clinical Trial	Yes, target	04/01/1900	04/01/1900	Yes a date	30/07/2018	10/05/2018	5 Recruitment finished
		number agreed			was agreed			
17/WS/0030	191416 A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in	Yes, target	02/01/1900		Yes a date		03/03/2018	0 Recruitment finished
	Different Combinations in Patients with Metastatic Pancreatic Ductal	number agreed			was agreed			
	Adenocarcinoma							
15/LO/1232	182226 Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose	Yes, target	03/01/1900		Yes a date	30/11/2017	30/11/2017	3 Recruitment finished
	Combination as an Adjunctive Therapy to a Prostaglandin Analogue	number agreed			was agreed			
16/YH/0081	186580 A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study	Yes, target	01/01/1900	01/01/1900	Yes a date	24/04/2018	24/04/2018	0 Recruitment finished
	Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active	number agreed			was agreed			
	Proliferative Lupus Nephritis.							
16/YH/0004	190267 A Phase II, Single Arm, Open-Label, Multicenter Study to Evaluate the Efficacy	Yes, target	01/01/1900	02/01/1900	Yes a date		07/11/2017	0 Recruitment finished
	and Safety of MOR00208 Combined with Idelalisib in Patients with Relapsed or	number agreed			was agreed			
	Refractory CLL/SLL Previously Treated with Bruton's Tyrosine Kinase (BTK)							
	Inhibitor							
16/NE/0023	190035 A Phase III, Multi-centre, Randomized, Double-Blind, Placebo-Controlled,	Yes, target	08/01/1900	08/01/1900	Yes a date	01/08/2018	01/08/2018	8 Recruitment finished
	Parallel-Group, Efficacy and Safety Study with Open-Label Extension of	number agreed			was agreed			
	Crenezumab in Patients with Prodromal-to-Mild Alzheimer's Disease							
15/YH/0434	185622 Dose Optimization Study of Idelalisib in Follicular Lymphoma and Small	Yes, target	02/01/1900		Yes a date	01/06/2019	01/08/2018	0 Withdrawn by Host
	Lymphocytic Lymphoma.	number agreed			was agreed			
16/LO/0351	190075 A double blind, randomized placebo controlled crossover multiple dose study of		07/01/1900		Yes a date	07/02/2018	07/02/2018	9 Recruitment finished
	LJN452 to assess safety, tolerability and efficacy in patients with primary bile	number agreed			was agreed			
	acid diarrhea (pBAD)							
16/LO/0124	182955 A study of the ReCor Paradise System in Clinical Hypertension	Yes, target	10/01/1900		Yes a date	17/12/2019	24/01/2018	11 Recruitment finished
		number agreed	1		was agreed	1		

15/WA/0358	1802//	An exploratory, open-label, multicenter study to evaluate the safety and	Yes, target	02/01/1900		Yes a date	10/03/2017	21/11/2017	3 Recruitment finished
13/ WA/0338	109544	efficacy of a two-dose regimen of ATIR101, a T-lymphocyte enriched leukocyte	number agreed			was agreed	10/03/2017	21/11/2017	S Reci ditinent inished
		preparation depleted ex vivo of host alloreactive T-cells (using photodynamic	indifiber agreed			was agreeu			
		treatment), in patients with a hematologic malignancy, who received a CD34-							
		selected hematopoietic stem cell transplantation from a haploidentical donor							
15/NW/0431	1773/16	A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy	Yes, target	02/01/1900		Yes a date	24/07/2017	01/12/2017	1 Recruitment finished
13/100/0431	1//340	and the Safety of Two Different Dose Regimens of a pan-FGFR Tyrosine Kinase	number agreed			was agreed	24/07/2017	01/12/2017	
		Inhibitor JNJ-42756493 in Subjects with Metastatic or Surgically Unresectable	number agreed			was agreeu			
		Urothelial Cancer with FGFR Genomic Alterations							
15/LO/2098	1921/17	A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy	Voc target	18/01/1900		Yes a date	01/02/2018	11/12/2017	2 Recruitment finished
13/10/2038	102147	and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and	number agreed			was agreed	01/02/2010	11/12/2017	
		Placebo in the Treatment of Patients with Moderate or Severe Acute	indifiber agreed			was agreeu			
15/LO/1538	100776	Respiratory Distress Syndrome A study to evaluate the effectiveness and safety of Exablate transcranial	Yes, target	10/01/1000	10/01/1900	Voc a dato	13/02/2019	26/10/2017	17 Recruitment finished
15/10/1538	199770		-		10/01/1900		13/02/2019	20/10/2017	17 Recruitment Imished
		MRgFUS thalamotomy treatment of medication refractory essential tremor	number agreed			was agreed			
1 E /NIE /01 C 7	171524	subjects	Vec torget	00/01/1000		Vac a data	25/11/2010	12/00/2018	
15/NE/0167	1/1524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral	Yes, target	06/01/1900		Yes a date	25/11/2019	12/09/2018	2 Recruitment finished
		Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly	number agreed			was agreed			
15404644	4005.00	Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation		05 /04 /4000	40/04/4000		01/11/2010	04/05/2010	
15/LO/1641	180563	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ, ¢	Yes, target		10/01/1900		01/11/2019	04/06/2018	16 Recruitment finished
		multielectrode	number agreed			was agreed			
		renal denervation system in Patients with Uncontrolled Hypertension in the							
15/10/11/00	404400	Absence of Antihypertensive Medications		20/04/4000	20/04/4000		24/42/2047	20/02/2040	
15/LO/1163	181430	A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1	Yes, target		30/01/1900		31/12/2017	30/03/2018	22 Recruitment finished
		Infected Subjects who are Virologically Suppressed on Regimens containing	number agreed			was agreed			
		ABC/3TC							
15/LO/1640	180561	Global Clinical Study of Renal Denervation with the Symplicity Spyralâ,,¢	Yes, target		10/01/1900		31/12/2019	03/05/2018	5 Withdrawn by Host
		multielectrode	number agreed			was agreed			
		renal denervation system in patients with uncontrolled hypertension on							
		standard medical therapy							
15/LO/0743	179335	A phase I, randomised, double-blind, placebo-controlled, multi-centre,	Yes, target		12/01/1900	no		31/10/2017	1 Recruitment finished
		ascending-dose trial to evaluate the safety, tolerability and immunogenicity of	number agreed						
		Vaccine FP-02.2 in HBeAg-negative hepatitis B patients as an add-on treatment							
		to entecavir or tenofovir.							
15/LO/0141	169126	The Efficacy and Safety of Bimatoprost SR in Patients With Openangle Glaucoma		01/01/1900		Yes a date		30/11/2017	2 Recruitment finished
		or Ocular Hypertension	number agreed			was agreed			
15/LO/1487	172859	A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with	no			Yes a date	01/08/2018	24/01/2018	Recruitment finished
		Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-				was agreed			
		Positive Metastatic Non-Small Cell Lung Cancer							
14/EM/1307	165983	A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT	Yes, target	14/01/1900		no		31/03/2018	0 Recruitment finished
		PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE	number agreed						
		LOCALLY ADVANCED OR METASTATIC BREAST CANCER							
13/EE/0214	128290	A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response	Yes, target		02/01/1900	Yes a date	14/02/2018	14/02/2018	2 Recruitment finished
		and/or Viral Risistance Patterns of Subjects with Chronic Hepatitis C Who Have	number agreed			was agreed			
		Been Previously Treated with MK-5172 in a Prior Clinical Trial							
09/H0724/39		Evaluation of Safety and Effectiveness of the FormulaTM PTMTM Balloon-	no			no		03/10/2017	0 Recruitment finished
		Expandable stent for Renal Artery Stenosis							
10/H0801/67	145462	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Risk Prostate	Yes, target	15/01/1900		Yes a date	31/07/2018	4 11/05/2018	4 Recruitment finished
		Cancer: Feasiblity Study	number agreed			was agreed			

11/EE/0256	Multi-centre, open label, prospective, consecutive series registry database of	Yes, target	10/01/1900	,	Yes a date	31/12/2016	01/06/2018	6	Recruitment finished
	BioPoly RS Partial Resurfacing Knee implant	number agreed		,	was agreed				